MultiplexDX offers its innovative solutions to biopharma companies and is open for strategic partnership for companion DX projects. MultiplexDX guarantees 100% precise cancer profiling and 100% accurate companion biomarker quantification by combining proprietary MDX visual and MDX sequencing technologies, which lead to cross-validation of quantitative data, thus eliminating errors. Our experts will provide you with all necessary details and available options particularly for your project requirements in the most effective, cost-efficient manner.
In our strategic partnership with you we will develop diagnostic tests and solutions to provide essential information for a safe and effective use of your corresponding drug, prospectively help to predict a likely response or severe toxicity and/or assist in making the optimal treatment decision possible for patients.
The diagnostic kits vDetect and rTest are based on an improved and re-designed Charité Berlin protocol also recommended by the WHO.
We offer custom, high quality synthesis of aptamers, siRNA, miRNA, antagomirs, qPCR probes, oligonucleotide triphosphates etc.
MDX small RNA sequencing products are compatible with Illumina sequencing technology and designed for the simplest, the most economical, the most precise and automated small RNA library preparation, enabling a great elimination of sequencing errors and biases.
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining our proprietary visual and sequencing technologies into one diagnostic test.
MultiplexDX offers a wide range of bioinformatics services, including genome assembly, gene expression, metagenomics analyses and data visualization.